ASCO Genitourinary Cancers Symposium

02/06/18

From February 8-10, the American Society of Clinical Oncology hosts its Genitourinary Cancers Symposium in San Francisco, California. The meeting will join members of the cancer care and research community who diagnose, treat, and study genitourinary malignancies to discover and share groundbreaking research. Journal of Clinical Pathways will be covering the most relevant abstracts leading up to and during the meeting.


ASCO
 
 
A recent study applied the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate and enzalutamide in advanced prostate cancer.
 
 
docetaxel
 
 
The addition of docetaxel to first-line long-term hormone therapy in prostate cancer improves overall health-related quality of life, reduces the need for further therapy, and is cost effective.
 
 
 
bladder

Trimodal Therapy vs Radical Cystectomy for Patients With Localized Bladder Cancer

Researchers compared the overall survival, cancer-specific survival, and associated costs of trimodal therapy versus radical cystectomy for patients with localized muscle-invasive bladder cancer.

Read More

HCR

 

Cost-Effectiveness of Hydrogel Rectal Spacer in Radiotherapy for Prostate Cancer

A recent cost-effectiveness analysis examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity modulated radiation therapy.

Read More

 

 

 

 

 

geriatric

 
 
A recent study evaluated the impact of a geriatric oncology clinic on cancer treatment plans and supportive care in older adults with genitourinary cancer.
 
 
 
Prostate

 

Cost-Effectiveness of Traditional Treatment vs Active Surveillance in Low-Risk Prostate Cancer

A cost-effectiveness analysis examined the use of a hydrogel rectal spacer in patients with prostate cancer undergoing intensity-modulated radiation therapy.

Read More